SB 200646 hydrochloride

Discontinued Product

1371 has been discontinued.

View all 5-HT<sub>2C</sub> Receptors products.
Description: 5-HT2C/2B antagonist
Chemical Name: N-(1-Methyl-1H-indol-5-yl)-N'-3-pyridinylurea
Purity: ≥98% (HPLC)
Datasheet
Citations (1)
Reviews
Literature (3)

Biological Activity for SB 200646 hydrochloride

SB 200646 hydrochloride is a 5-HT2C/2B receptor antagonist, selective over 5-HT1A. Affinities are 7.4 (pA2), 6.9 (pKi) and 5.2 (pKi) for 5-HT2B, 2C and 2A respectively. Orally active in vivo.

Licensing Information

Sold under license

Technical Data for SB 200646 hydrochloride

M. Wt 302.76
Formula C15H14N4O.HCl
Storage Store at RT
Purity ≥98% (HPLC)
CAS Number 143797-62-0
PubChem ID 5311422
InChI Key IGRYPUQJEDJLHC-UHFFFAOYSA-N
Smiles Cl.CN1C=CC2=CC(NC(=O)NC3=CN=CC=C3)=CC=C12

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Product Datasheets for SB 200646 hydrochloride

Certificate of Analysis / Product Datasheet
Select another batch:

References for SB 200646 hydrochloride

References are publications that support the biological activity of the product.

Forbes et al (1993) N-(1-Methyl-5-indolyl)-N'-(3-pyridyl)urea hydrochloride: the first selective 5-HT1C receptor antagonist. J.Med.Chem. 36 1104 PMID: 8478907

Kennett et al (1994) In vivo properties of SB 200646A, a 5-HT2C/2B recepor antagonist. Br.J.Pharmacol. 111 797 PMID: 7912626

Kennett et al (1995) Effect of SB 200646A, a 5-HT2C/5-HT2B receptor antagonist, in two conflict models of anxiety. Psychopharmacology (Berl.) 118 178 PMID: 7617805

View Related Products by Target

View Related Products by Product Action

View all 5-HT2C Receptor Antagonists

Keywords: SB 200646 hydrochloride, SB 200646 hydrochloride supplier, 5-HT2C/2B, antagonists, Serotonin, 5-HT2B, Receptors, SB200646, hydrochloride, 5-HT2C, 1371, Tocris Bioscience

1 Citation for SB 200646 hydrochloride

Citations are publications that use Tocris products. Selected citations for SB 200646 hydrochloride include:

Xiao et al (2008) Release of glutamate and CGRP from trigeminal ganglion neurons: Role of calcium channels and 5-HT1 receptor signaling. Am J Physiol Endocrinol Metab 4 12 PMID: 18416824


Reviews for SB 200646 hydrochloride

There are currently no reviews for this product. Be the first to review SB 200646 hydrochloride and earn rewards!

Have you used SB 200646 hydrochloride?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


5-HT Receptors Scientific Review

5-HT Receptors Scientific Review

Written by Nicholas M. Barnes and John F. Neumaier, this review summarizes the various serotonin receptor subtypes and their importance in mediating the role of serotonin in numerous physiological and pharmacological processes. Compounds available from Tocris are listed.

Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.